Compositions and methods for the treatment and diagnosis of cardiovascular disease
AssigneeMillennium Pharmaceuticals, Inc.
InventorsDean A. Falb, Michael A. Gimbrone JR.
Life of this patent
Estimating the term…
Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsDean A. Falb, Michael A. Gimbrone JR.
Estimating the term…
The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.
An isolated polynucleotide comprising a nucleotide sequence (a) encoding a polypeptide having the amino acid sequence set forth in FIG. 9, or (b) encoding a polypeptide encoded by the rchd534-long cDNA contained in the clone pHL6TA1A, as deposited with the American Type Culture Collection as Accession No. 209615, or (c) which is the complement of (a) or (b).
An isolated polynucleotide comprising the nucleotide sequence (a) of the rchd534-long cDNA as shown in FIG. 9, or (b) of the rchd534 cDNA insert contained in the clone pHL6TA1A, as deposited with the American Type Culture Collection as Accession No. 209615, or (c) which is the complement of (a).
An isolated polynucleotide comprising the nucleotide sequence (a) of the rchd534-long polypeptide coding region, which coding region is set forth from nucleotide residue number 155 to 494 of FIG. 9, or (b) of the polypeptide coding region of the rchd534-long cDNA contained in the clone pHL6TA1A, as deposited with the American Type Culture Collection as Accession No. 209615, or (c) which is the complement of (a) or (b).
A method for identifying a substance for treating cardiovascular disease comprising assaying the ability of the substance to modulate the expression of the rchd534 gene, or the activity of the rchd534 or rchd534-long protein.
An assay for identifying a substance that binds to the rchd534-long protein, comprising:
An assay for identifying a substance that inhibits the interaction between the rchd534-long protein and the fchd540 protein comprising:
An assay for identifying a substance that inhibits the interaction between two rchd534-long protein molecules comprising:
An assay for identifying a substance that inhibits the interaction between the rchd534-long protein and a protein member of the TGF-β signalling pathway comprising:
An assay for identifying a substance that inhibits the interaction between the fchd540 protein and a protein member of the TGF-β signalling pathway comprising:
A method for treating cardiovascular disease comprising administering a compound that inhibits the interaction between the rchd534-long protein and the fchd540 protein.
A method for treating cardiovascular disease comprising administering a compound that inhibits the interaction between two rchd534-long protein molecules.
A method for treating cardiovascular disease comprising administering a compound that inhibits the interaction between the rchd534-long protein and a protein member of the TGF-β signalling pathway.
A method for treating cardiovascular disease comprising administering a compound that inhibits the interaction between the fchd540 protein and a protein member of the TGF-β signalling pathway.
A method for identifying a substance that enhances the TGF-β signalling response comprising:
A method for identifying a substance for treating fibroproliferative disease or oncogenic related disorders comprising assaying the ability of the substance to modulate expression of, or the activity of the encoded protein product of, the rchd534-long spliceoform or the fchd540 gene.
A method for treating fibroproliferative disease or oncogenic related disorders comprising administering a compound that inhibits the interaction between the rchd534-long protein and a protein member of the TGF-β signalling pathway.
A method for treating fibroproliferative disease or compound that inhibits the interaction between the rchd534-long protein and the fchd540 protein.
Dependencies are inferred from the claim text.